Amgen's Dazodalibep Shines in Sjogren's Disease Trial
Amgen's experimental drug dazodalibep has shown significant promise in treating Sjogren's disease, an autoimmune condition that affects about 1% of the global population and predominantly impacts women. In a late-stage trial, dazodalibep demonstrated statistically significant improvement in patients with moderate-to-severe disease activity at week 48.
The drug achieved a clinically meaningful reduction in disease activity, which is a crucial milestone for Amgen as it seeks to bring an approved treatment for Sjogren's disease to the market. The trial results were greeted positively by investors, with Amgen's shares rising 4% in morning trading.
While analysts praised the promising trial outcomes, some noted that several details necessary for investors were absent from the announcement. These include full trial data and a comparison of dazodalibep's performance against Novartis' ianalumab, which is also being developed to treat Sjogren's disease.
Amgen plans to present detailed data from the trial at an upcoming medical meeting, while a separate trial, OASIZ 303, will provide further insights into the drug's efficacy. The company expects results from this trial in the fourth quarter of 2026 and may outline regulatory and filing plans after the readout.